Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07807826
PHASE3

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)

Sponsor: Beijing Keymed Biosciences Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)

Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2026-10

Completion Date

2028-07

Last Updated

2026-09-08

Healthy Volunteers

No

Interventions

BIOLOGICAL

CM512

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Locations (1)

Beijing Tongren Hospital, CMU

Beijing, Beijing Municipality, China